For clinical trials · CLIA-validated panel

Cognilera® for clinical trials: Alzheimer’s pathology and neuronal injury from one blood draw

Cognilera, developed by NeuroDex, measures p-Tau217, the Aβ42/40 ratio, GFAP and NfL from a single blood draw in a CLIA-certified laboratory. Trial teams can use these validated markers to characterize Alzheimer’s pathology in participants at baseline and to follow neuronal injury across visits.

  • 4 markersOne drawp-Tau217, Aβ42/40 ratio, GFAP and NfL.
  • ≤14 daysReport turnaroundTiered, flagged and reviewed by the laboratory director.
  • CLIAValidated, locked protocolAutomated clinical immunoassay platforms with QC on every run.

How trial teams use Cognilera

One panel for participant characterization in cognitive studies

01

Characterize Alzheimer’s pathology

A blood-based read on Alzheimer’s pathology at baseline. In NeuroDex internal validation against amyloid PET, p-Tau217 showed 96% sensitivity and 97% specificity (11% indeterminate).

p-Tau217 · Aβ42/40 ratio

02

Follow neuronal injury across visits

Markers of neuronal injury and astrocyte activation from routine plasma, with every result reported against reference intervals and decision limits.

NfL · GFAP

03

Add brain-derived biomarkers

Pair the panel with NeuroDex’s brain-derived vesicle assays for TDP-43, α-synuclein and CNS target engagement in the same study.

Clinical trial services

Two panel options

Full panel

Cognilera® Complete

All four Tier 1 markers for Alzheimer’s pathology and neuronal injury, reported together in one result.

Cognilera Complete

Focused pathology test

Cognilera® p-Tau217

Plasma p-Tau217 on its own, when the question is narrow. Any p-Tau217 result can be extended to Complete on the same specimen.

Cognilera p-Tau217

The core panel: Alzheimer’s pathology and neuronal injury

Tier 1 — Detect

Alzheimer’s pathology (p-Tau217, Aβ42/40 ratio) and neuronal injury and astrocyte activation (NfL, GFAP).

p-Tau217Aβ42/40 ratioGFAPNfL

Specimen and site logistics

SpecimenPlasma, separated at the collection site after a routine venous draw
Site equipmentBenchtop centrifuge, collection kits, shipping materials and staff training supplied at no charge
TurnaroundResults reported within 14 days
ReportingEvery analyte reported against reference intervals and clinical decision limits, tiered and flagged, and reviewed by the laboratory director before release
QualityCLIA- and GCLP-validated, with a locked assay protocol and quality control on every run

Add Cognilera to your next cognitive study.

Important information. Cognilera tests are laboratory-developed tests performed by SBH Diagnostics, 4 Strathmore Road, Natick, MA 01760 (CLIA #22D2060724). They have not been cleared or approved by the U.S. Food and Drug Administration. They are intended for adults under clinical evaluation for cognitive impairment and are not a screening test. Results should be interpreted by a qualified healthcare professional as one component of a clinical evaluation and are not a diagnosis on their own.

Performance figures are from NeuroDex internal validation. Alpha-synuclein and TDP-43 are in development and are not part of the reportable Cognilera panel. For clinical ordering, visit cognilera.com. Cognilera is a NeuroDex Inc. brand.